- Home
- ACRE vs PBYI Comparison
ACRE vs PBYI Comparison
Compare ACRE & PBYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ACRE | PBYI |
|---|---|---|
| Founded | 2011 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 254.1M | 263.4M |
| IPO Year | 2012 | N/A |
Fundamental Metrics
Financial Performance| Metric | ACRE | PBYI |
|---|---|---|
| Price | $5.23 | $5.82 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 1 |
| Target Price | $5.08 | ★ $7.00 |
| AVG Volume (30 Days) | ★ 400.1K | 389.6K |
| Earning Date | 11-07-2025 | 11-06-2025 |
| Dividend Yield | ★ 11.52% | N/A |
| EPS Growth | N/A | ★ 59.87 |
| EPS | N/A | ★ 0.74 |
| Revenue | $87,777,000.00 | ★ $211,995,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $7.80 |
| Revenue Growth | ★ 122.65 | N/A |
| 52 Week Low | $3.35 | $2.58 |
| 52 Week High | $7.27 | $6.12 |
Technical Indicators
Market Signals| Indicator | ACRE | PBYI |
|---|---|---|
| Relative Strength Index (RSI) | 60.64 | 67.11 |
| Support Level | $5.02 | $4.84 |
| Resistance Level | $5.27 | $5.11 |
| Average True Range (ATR) | 0.13 | 0.20 |
| MACD | -0.01 | 0.09 |
| Stochastic Oscillator | 70.59 | 99.01 |
Price Performance
Historical ComparisonAbout ACRE Ares Commercial Real Estate Corporation
Ares Commercial Real Estate Corp is a specialty finance company and a Real Estate Investment Trust providing commercial real estate loans and related investments. It operates in one segment namely originating and managing a diversified portfolio of CRE debt-related investments. The group recognizes its revenues through the interest income it receives from loans.
About PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis resulting into apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.